Galliprant

Search documents
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
Prnewswire· 2025-07-24 21:42
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe ...
Elanco(ELAN) - 2024 Q4 - Earnings Call Transcript
2025-02-25 15:59
Elanco Animal Health Incorporated (NYSE:ELAN) Q4 2024 Earnings Conference Call February 25, 2024 8:00 AM ET Company Participants Tiffany Kanaga - Head of IR Jeffrey Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Daniel Clark - Leerink Partners Andrea Alfonso - UBS Erin Wright - Morgan Stanley Balaji Prasad - Barclays Mike DiFiore - Evercore ISI Chris Schott - JPMorgan David Westenberg - Piper Sandler Operator Ladies and ...